PN6047 Hydrochloride Salt Crystalline Forms for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical forms of PN6047, a potent 6-opioid receptor agonist, face challenges with low chemical and physical stability, high residual solvent levels, and variable solubility, which affect its handling and efficacy in pain management.
Innovation Solution
Development of stable crystalline hydrochloride salts, specifically Forms HCl2 and HCl3, with improved solubility, bioavailability, and low hygroscopicity, achieved through crystallization from organic solvents and controlled humidity conditions, enhancing their stability and pharmaceutical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If non-crystalline (amorphous) forms of PN6047 are used, then solubility may be improved, but chemical and physical stability deteriorates and residual solvent levels increase
Solution Approach 1:
The patent applies phase transition by converting the amorphous phase to crystalline phases (Forms HCl1, HCl2, HCl3) of the hydrochloride salt. This phase change from amorphous to crystalline state resolves the contradiction by providing a stable solid form with defined solubility characteristics while eliminating the instability and high residual solvent problems associated with amorphous materials.
Solution Approach 2:
The patent changes the physical and chemical parameters by forming hydrochloride salts of PN6047. This parameter change from free base to hydrochloride salt form, combined with specific crystallization conditions, achieves both improved solubility and enhanced stability, resolving the technical contradiction.
2Quantity of substance
If amorphous materials are used, then initial solubility may be enhanced, but decomposition rate increases and handling difficulty increases
Solution Approach 1:
By transitioning from amorphous to crystalline phases through controlled crystallization, the patent provides a stable solid form that is easy to handle, store, and process. The crystalline forms maintain solubility while eliminating the handling difficulties and decomposition issues of amorphous materials.
3Reliability
If crystalline forms with high crystallinity are achieved, then stability and handling improve, but solubility may be reduced
Solution Approach 1:
The patent changes the chemical parameter by forming hydrochloride salts, which inherently have improved solubility compared to the free base. This parameter change allows achieving high crystallinity with good solubility, resolving the contradiction between crystallinity and solubility.
Solution Approach 2:
The patent creates composite crystalline structures (Forms HCl1, HCl2, HCl3) with specific molecular arrangements that balance stability and solubility. These composite crystalline forms achieve both high crystallinity for stability and appropriate solubility for pharmaceutical effectiveness.
4Reliability
If multiple polymorphic forms are discovered, then solubility and stability can be optimized, but manufacturing complexity increases
Solution Approach 1:
The patent identifies multiple crystalline phases (HCl1, HCl2, HCl3) that can be obtained through different phase transition pathways using various solvents. While multiple forms exist, each has defined characterization data and reproducible preparation methods, which manages manufacturing complexity while providing options for optimizing stability and solubility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms exhibit increased bioavailability and solubility, leading to improved pain management with reduced side effects and potential for sustained release formulations, while maintaining stability across various humidity and temperature conditions.
Implementation Method 1
Development of stable crystalline hydrochloride salts, specifically Forms HCl2 and HCl3, with improved solubility, bioavailability, and low hygroscopicity, achieved through crystallization from organic solvents and controlled humidity conditions
Data Source
AI summary
The present invention relates to a hydrochloride salt of 4-[(3-carbamoylphenyl)[1-(1,3-thiazol-5-ylmethyl)piperidin-4-ylidene]methyl]-N,N-dimethylbenzamide (PN6047) and crystalline forms thereof, more specifically Form HCl2 and Form HCl3 of PN6047. The invention also relates to pharmaceutical compositions comprising such polymorphs, to a process for the preparation of these polymorphs, and to the use of these polymorphs in the treatment or prevention of conditions that are mediated by agonism of the δ-opioid receptor, and in particular in the treatment or prevention of pain.